Home > Collaborators

CollaboraTIONs

1/ Intramural

School of Medicine

  Department of Biostatistics

• Phyllis Gimotty: Study of molecular variants of complement factor H in ovarian cancer

  Department of Gastroenterology

• David Kaplan and Yonghai Li: Development of ScFv specific for human glypican-3 for adoptive T cell therapy of liver cancer

  Departement of Hematology-Oncology

• Gween Danet-Desnoyers: Study of a humanized mouse model of ovarian cancer

  Department of Obstetrics and Gynecology

• Center for Research on Reproduction and Women's Health (CRRWH)
  • Michal A. Elovitz: Contribution of the immune response in maternal mortality from systemic illness
• George Gerton: Development of targeted nanoparticles as non-surgical sterilizing agents
• Penn Ovarian Cancer Research Center (Penn OCRC)
  • George Coukos: anti-TEM1 scFv for targeted therapy and imaging; role of complement in cancer.
  • Daniel J. Powell Jr.: Generation of CIRs for adoptive T cell therapy of ovarian cancer

  Department of Pathology & Laboratory Medicine

• John Lambris: Role of complement in ovarian cancer.
• Don Siegel : Construction of scFv libraries
• Michael Feldman: Analysis of B cells and macrophages in ovarian cancer microarrays.

   Department of Radiology

• Chatanya Divgi, Kolin Hribar and Gregory Wiedman: scFv functionalization of nanorods
• Jerry Glickson: Folate receptor, TEM1 and mesothelin targeted imaging
• Vladimir Muzykantov: radiolabeling of scFv via ester coupling of labeled tin-polymer

School of Engineering and Applied Science

   Department of Material Science

• Christopher B. Murray: Development of targeted superparamagnetic iron oxide nanoparticles (SPIONs)

 

2/ Extramural collaborations and/or material exchange via MTA.

A) National 

a) Academia

Drexel Institute for Biotechnology & Virology Research, Institute for Hepatitis & Virus Research, PA

• Timothy Block and Patrick R. Romano: yeast-display libraries of lectins for generation of high affinity reagents against glycans

John Hopkins University, Baltimore, MA

• Junbiao Dai: pAGA2 and p416-BCCP plasmids to produce soluble proteins, peptides or recombinant antibodies in yeast.

Harvard University, Cambridge, MA

• David R. Liu: src kinase inhibitors
• Andrew Murray: pTOR2 and pTOR BIR bearing yeast
• Tom A. Rapoport: pTOR BIR bearing yeast

Institute for Systems Biology, Seattle WA (Past)

• Daniel Martin: Yeast-display scFv library for high-throughput identification of anti-peptides affinity reagents for SISCAPA usage

Providence Portland Medical Center, Portland, OR

• Hong-Ming Hu: Yeast-display scFv library, p416-BCCP vector and pTOR BIR bearing yeast for identification of c-type specific lectins anti-scFv

University of California, San Diego, CA

• Shaochen Chen and Kolin C. Hribar, Department of NanoEngineering: Targeted nanoparticles

University of Georgia, Complex Carbohydrate Research Center, Athens, GA

• Karen L. Abbott and Michael Pierce: Role of GPI anchors in the tumor microenvironment and development of affinity reagents.

University of Texas, MD Anderson Cancer Center, Houston, TX

• Laurence Cooper: Yeast-display library of scFv.

University of Washington, Seattle, WA

• Andre Lieber: Desmoglein 1 study.

Vanderbuilt University, Nashville, TN

• Robert Carnahan: pAGA2 and p416-BCCP plasmids for yeast secretion, and pTOR BirA bearing yeast for production of Biobodies and coupling to sensors for quantitative analysis.

b) Interface academia/Biotech companies

Dana Farber/Boston BioCom, Boston, MA

• Mark Poznanzki and Jeffrey Gelfand: anti-mesothelin scFv fused to tetanus toxin for targeted therapy of ovarian cancer

c) Biotech companies

Amplimmune, Inc, Gaithersburg, MD

• Reagents directed against B7-H4.

Centocor, Malvern, PA

• Characterisation of a NSG-HIS mouse model of ovarian cancer.

Intelligent Optical Systems, Inc., Torrance, CA

• Srivatsa Venkatasubbarao: Biobodies for development of strip ELISAs

Lifesensors, Malvern, PA

• Tauseef Butt and Christian Loch: high yield production of biobodies in Pichia

B) International 

a) Academia

Democritus University of Thrace, Department of Molecular Biology and Genetics, Greece.

• Raphael Sandaltzopoulos: role of GPI anchors in the tumor-microenvironment.

INSERM, Technological Advances for Genomics and Clinics (TAGC), Marseille-Luminy, France.

• Catherine Nguyen, Daniel Baty and Patrick Chames: isolation of antigen-specific scFv and nanobodies.

Universite Pierre et Marie Curie, Departement de Biochimie, Ecole de Medecine Saint-Antoine, France.

• Claude Wolf and Antonin Lamaziere: lipid analysis of tumor-released GPI anchors.

University of Queensland, Bioengineering & Nanotechnology (AIBN), Brisbane, Australia. 

• Matt Trau, scFv coated: bar-coded nanoparticles for biomarker discovery.

University of Sao Paulo, Department of Clinical Medicine, Ribeirao Preto, MG, Brazil.

• Ana Maria Roselino: Desmoglein 1 study.

 

b) Biotech company

AbGenics, National Chemical Laboratory Innovation Park, Pune, India.

• Sanjiban Banerjee: yeast-display library platform.